Impact of Climate Change on Pollen and Respiratory Disease

AbstractPurpose of ReviewA warming world will impact everyone and everything. The practice of allergic and respiratory disease will not be excepted. All the impacts will be impossible to anticipate. This review is intended to discuss significant factors related to individuals with allergic and respiratory disease.Recent FindingsRecent findings include the increased growth of allergenic plants in response to higher carbon dioxide levels and warmer temperatures. This also contributes to the increased production of pollen as well as the appearance of allergenic species in new climactic areas. Stinging insects will extend their ranges into northern areas where they have not previously been a problem. The shift and extension of pollen seasons with warmer springs and later frosts have already been observed. Recent severe hurricanes and flooding events may be just the harbinger of increasing damp housing exposure related to sea level rise. Evidence is accumulating that indicates the expected higher number of ozone alert days and increased pollution in populated areas is bringing increases in pollen potency. Finally, increased exposure to smoke and particles from wild fires, resulting from heat waves, will contribute to the general increase in respiratory disease.SummaryThe practice of allergy being closely aligned with environmental conditions will be especially impacted. Allergists should consider increasing educational activities aimed at making patients more aware of air quality ...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research

Related Links:

Asthma education and asthma action plans provided in 21.4 and 9.9 percent of asthma visits, respectively
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Allergy, Nursing, Pulmonology, Journal, Source Type: news
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Chronic rhinosinusitis is a long-lasting medical condition, usually caused by infection or exposure to irritants, such as allergies, that affects one in seven American adults. Symptoms include nasal obstruction, nasal congestion, nasal drainage, loss of smell and taste, and facial pain and pressure. Some people with chronic rhinosinusitis also develop additional symptoms, such as asthma and nasal polyps, that are exacerbated by underlying allergies. A nasal polyp is a noncancerous tumor that grows from the lining of the nose or sinuses and affects the drainage system of the sinuses. While chronic rhinosinusitis is not a li...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Allergies Cold and Flu Drugs and Supplements Ear, nose, and throat Health Source Type: blogs
ConclusionsIn asthmatic patients, nocturnal CoFr can be associated with BHR, was significantly higher before treatment, but improved more after treatment compared to non-asthmatic patients. Monitoring nocturnal CoFr may provide unique and valuable information on making an early prediction of therapeutic effects in asthma.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 18 September 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Marcia Vervloet, Liset van Dijk, Peter Spreeuwenberg, David Price, Alison Chisholm, Eric Van Ganse, Hilary Pinnock, Cynthia S. Rand, Michelle N. Eakin, Tjard Schermer, Patrick C. Souverein, Alexandra L. Dima, Respiratory Effectiveness Group’s Adherence Working GroupAbstractBackgroundLow inhaled corticosteroids (ICS) adherence is associated with increased asthma burden. This relationship is likely bidirectional, and may vary across adherence stages (initiation, implementation, persistence)....
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
SOMERVILLE (CBS) – A Somerville widower is sharing a life and death warning to asthmatics and their families. “If you love someone with asthma, they need to be extra careful this week,” said Peter DeMarco. DeMarco remembers his wife, Laura Levis, as “funny, and smart and so beautiful.” The active and adventurous young woman collapsed from an asthma attack outside a locked entrance to Somerville Hospital in 2016. Laura Levis (Courtesy photo) “She was 34 years old. There’s no way she ever thought asthma could end her life… I wish I was with her. So much. I wasn’t,”...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Syndicated CBSN Boston Syndicated Local Watch Listen Asthma Asthma Peak Week Juli McDonald Somerville News Source Type: news
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Publication date: Available online 18 September 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Renaud Louis, Nicolas Bougard, Françoise Guissard, Virginie Paulus, Monique Henket, Florence SchleichAbstractBackgroundMethacholine bronchial challenge and bronchodilation to salbutamol are key tests in clinical practice to make asthma diagnosis.ObjectiveTo assess the concordance between the two tests and to see whether they actually identify the same population of asthmaticsMethodWe conducted a retrospective study using our asthma clinic database to see how methacholine bronchial challen...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
ConclusionThe trial demonstrated a favorable safety profile of the SQ HDM SLIT-tablet in Japanese adult patients with AA. The treatment appeared to be efficacious in patients requiring rescue medication (i.e., SABA) at baseline in the efficacy assessment using asthma exacerbation during ICS reduction (JapicCTI number 121847).
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Education | Environmental Health | Respiratory Medicine